Bone turnover, bone mineral density, and fracture risk in acromegaly: A meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 384-394

  Mazziotti, Gherardo ^a   Biagioli, Elena ^b   Maffezzoni, Filippo ^a   Spinello, Maurizio ^c   Serra, Vincenza ^a   Maroldi, Roberto ^a   Floriani, Irene ^b   Giustina, Andrea ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Italy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACROMEGALY; BONE DENSITY; BONE FRAGILITY; BONE TURNOVER; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FEMUR NECK; FRACTURE; HUMAN; HYPOGONADISM; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPINE FRACTURE; STUDY DESIGN; BONE REMODELING; COMPLICATION; FRACTURES, BONE; LUMBAR VERTEBRA; META ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOGRAPHY; RISK;

ACROMEGALY; BONE DENSITY; BONE REMODELING; FEMUR NECK; FRACTURES, BONE; HUMANS; LUMBAR VERTEBRAE; RISK;

EID: 84922571853     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2937     Document Type: Review

References (88)

1. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008; 29: 535-559.
2. Doga M, Bonadonna S, Gola M, Mazziotti G, Nuzzo M, Giustina A. GH deficiency in the adult and bone. J Endocrinol Invest. 2005; 28(8 suppl): 18-23.
3. Kamenický P, Mazziotti G, Lombès M, Giustina A, Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev. 2014; 35: 234-281.
4. Albright F, Reifenstein EC. The Parathyroid Glands and Metabolic Bone Disease: Selected Studies. Baltimore, MD: Williams & Wilkins; 1948: 188-196.
5. Riggs BL, Randall RV, Wahner HW, Jowsey J, Kelly PJ, Singh M. The nature of the metabolic bone disorder in acromegaly. J Clin Endocrinol Metab. 1972; 34: 911-918.
6. Halse J, Melsen F, Mosekilde L. Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol. 1981; 97: 18-22.
7. Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL. Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest. 1982; 69: 1302-1309.
8. Hübsch P, Kotzmann H, Svoboda T, Kainberger FM, Bankier A, Seidl G. Bone density of the lumbar spine and femur in acromegaly [in German]. Radiologe. 1993; 33: 457-461.
9. Kaji H, Sugimoto T, Nakaoka D, et al. Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf). 2001; 55: 175-181.
10. Diamond T, Nery L, Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med. 1989; 111: 567-573.
11. Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab. 1993; 76: 1452-1457.
12. Ho PJ, Fig LM, Barkan AL, Shapiro B. Bone mineral density of the axial skeleton in acromegaly. J Nucl Med. 1992; 33: 1608-1612.
13. Kotzmann H, Bernecker P, Hübsch P, et al. Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res. 1993; 8: 459-465.
14. Kayath MJ, Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int. 1997; 7: 226-230.
15. Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly - a potential beneficial effect of growth hormone. Osteoporos Int. 2004; 15: 155-159.
16. Ueland T, Ebbesen EN, Thomsen JS, et al. Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Invest. 2002; 32: 122-128.
17. Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res. 2005; 20: 1837-1844.
18. Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab. 2008; 93: 4649-4655.
19. Battista C, Chiodini I, Muscarella S, et al. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin Endocrinol (Oxf). 2009; 70: 378-382.
20. Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur JEndocrinol. 2011; 164: 475-483.
21. Padova G, Borzì G, Incorvaia L, et al. Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clin Cases Miner Bone Metab. 2011; 8: 37-43.
22. Madeira M, Neto LV, Torres CH, de Mendonça LM, Gadelha MR, de Farias ML Vertebral fracture assessment in acromegaly. J Clin Densitom. 2013; 16: 238-243.
23. Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab. 2013; 98: 3402-3410.
24. Claessen KM, Kroon HM, Pereira AM, et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab. 2013; 98: 4808-4815.
25. Brzana J, Yedinak CG, Hameed N, Fleseriu M. FRAX score in acromegaly: does it tell the whole story? Clin Endocrinol (Oxf). 2014; 80: 614-616.
26. Mazziotti G, Gola M, Bianchi A, et al. Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine. 2011; 40: 102-108.
27. Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A. New understanding and treatments for osteoporosis. Endocrine. 2012; 41: 58-69.
28. Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest. 2003; 26: 1242-1247.
29. Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013; 16: 294-302.
30. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011; 14: 284-294.
31. Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011; 22: 391-420.
32. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: anupdate. Contemp Clin Trials. 2007; 28: 105-114.
33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560.
34. Stepan J, Marek J, Havránek T, Dolezal V, Pacovský V. Bone isoenzyme of serum alkaline phosphatase inacromegaly. Clin Chim Acta. 1979; 93: 355-363.
35. Tabolli S, Bigi F, Valtorta C, Minisola S, Mazzuoli GF. Normal calcitonin secretion in acromegaly. Horm Res. 1987; 25: 1-4.
36. de la Piedra C, Larrañaga J, Castro N, et al. Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly. Calcif Tissue Int. 1988; 43: 44-45.
37. Legovini P, DeMenis E, Doroldi C, et al. Parathormonelevels during treatment of acromegaly with octreotide: one year follow-up. Curr Ther Res. 1993; 53: 360-366.
38. Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marín F, Lucas T. Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int. 1993; 52: 419-421.
39. Piovesan A, Terzolo M, Reimondo G, et al. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Horm Metab Res. 1994; 26: 234-237.
40. Jockenhövel F, Rohrbach S, Deggerich S, Reinwein D, Reiners C. Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res. 1996; 1: 377-382.
41. Scillitani A, Chiodini I, Carnevale V, et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res. 1997; 12: 1729-1736.
42. Lesse GP, Fraser WD, Farquharson R, Hipkin L, Vora JP. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf). 1998; 48: 59-65.
43. Longobardi S, Di Somma C, Di Rella F, et al. Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest. 1998; 21: 688-693.
44. Bolanowski M, Wielgus W, Milewicz A, Marciniak R. Axial bone mineral density in patients with acromegaly. Acad Radiol. 2000; 7: 592-594.
45. Ueland T, Bollerslev J, Godang K, Müller F, Frøland SS, Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol. 2001; 145: 685-690.
46. Minisola S, Dionisi S, Pacitti MT, et al. Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int. 2002; 13: 171-175.
47. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnoverto normal. J Clin Endocrinol Metab. 2003; 88: 5650-5655.
48. Scillitani A, Battista C, Chiodini I, et al. Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clin Endocrinol (Oxf). 2003; 58: 725-731.
49. Matsuyama J, Eshima N, Fukunaga T, Hori S, Kobayashi H, Isono M. Various risks of osteoporosis in patients with pituitary adenomas. J Bone Miner Metab. 2003; 21: 91-97.
50. Tütüncü NB, Erba T. Factors associated with bone metabolism in acromegalic patients: hypogonadism and female gender. Exp Clin Endocrinol Diabetes. 2004; 112: 328-332.
51. Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. Eur J Endocrinol. 2005; 152: 53-60.
52. Bolanowski M, Daroszewski J, Medra M, Zadrozna-Sliwka B. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab. 2006; 24: 72-78.
53. Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol. 2006; 155: 709-715.
54. White HD, Ahmad AM, Durham BH, et al. Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab. 2006; 91: 913-919.
55. Kastelan D, Dusek T, Kraljevic I, et al. Bone properties in patients with acromegaly: quantitative ultrasound of the heel. J Clin Densitom. 2007; 10: 327-331.
56. Zgliczynski W, Kochman M, Misiorowski W, Zdunowski P. In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender. Neuro Endocrinol Lett. 2007; 28: 621-628.
57. Sucunza N, Barahona MJ, Resmini E, et al. Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol. 2008; 159: 773-779.
58. Sucunza N, Barahona MJ, Resmini E, et al. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab. 2009; 94: 3889-3896.
59. Madeira M, Neto LV, de Lima GA, et al. Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly. Osteoporos Int. 2010; 21: 2019-2025.
60. Madeira M, Neto LV, de Paula Paranhos Neto F, et al. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2013; 98: 1734-1741.
61. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007; 357: 905-916.
62. Mazziotti G, Bianchi A, Bonadonna S, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res. 2006; 21: 520-528.
63. Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab. 2014; 99: 852-860.
64. Renier G, Clément I, Desfaits AC, Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-α production. Endocrinology. 1996; 137: 4611-4618.
65. Uronen-Hansson H, Allen ML, Lichtarowicz-Krynska E, et al. Growth hormone enhances proinflammatory cytokine production by monocytes in whole blood. Growth Horm IGF Res. 2003; 13: 282-286.
66. Örük G, Tarhan F, Argin M, Özmen M. Is every joint symptom related to acromegaly? Endocrine. 2013; 43: 404-411.
67. Romijn JA Acromegalic arthropathy: current perspectives. Endocrine. 2013; 43: 245-246.
68. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992; 7: 221-227.
69. Griffith JF, Genant HK. New advances in imaging osteoporosis and its complications. Endocrine. 2012; 42: 39-51.
70. Jalava T, Sarna S, Pylkkänen L, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res. 2003; 18: 1254-1260.
71. Cauley JA, Hochberg MC, Lui LY, et al. Long-term risk of incident vertebral fractures. JAMA. 2007; 298: 2761-2767.
72. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000; 15: 1384-1392.
73. Murray RD, Peacey SR, Rahim A, Toogood AA, Thorner MO, Shalet SM. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients. Clin Endocrinol (Oxf). 2001; 54: 37-44.
74. Bolanowski M, Pluskiewicz W, Adamczyk P, Daroszewski J. Quantitative ultrasound at the hand phalanges in patients with acromegaly. Ultrasound Med Biol. 2006; 32: 191-195.
75. Ulivieri FM, Silva BC, Sardanelli F, Hans D, Bilezikian JP, Caudarella R. Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine. 2014; 47: 435-448.
76. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2007; 92: 1743-1747.
77. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. J Clin Endocrinol Metab. 2009; 94: 1500-1508.
78. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012; 7: e36411.
79. Carmichael JD, Bonert VS, Nuño M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014; 99: 1825-1833.
80. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000; 85: 526-529.
81. Giustina A, Chanson P, Bronstein MD, et al. Aconsensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010; 95: 3141-3148.
82. Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014; 10: 243-248.
83. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002; 21: 1559-1573.
84. Mancini T, Mazziotti G, Doga M, et al. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone. 2009; 45: 784-788.
85. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med. 2010; 123: 877-884.
86. Giustina A, Karamouzis I, Patelli I, Mazziotti G. Octreotide for acromegaly treatment: a reappraisal. Expert Opin Pharmacother. 2013; 14: 2433-2447.
87. Marazuela M, Ramos-Leví A, Sampedro-Núñez M, Bernabeu I. Cabergoline treatment in acromegaly: pros. Endocrine. 2014; 46: 215-219.
88. Giustina A, Ambrosio MR, Beck Peccoz P, et al. Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest. 2014; 37: 1017-1030.